DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Comparison of Retinol 1.0% and Tretinoin 0.02% in the Treatment of Moderate to Severe Photodamage and Wrinkles

Information source: Johns Hopkins University
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Photodamaged Skin; Wrinkles

Intervention: Retinol (Drug); Tretinoin (Drug)

Phase: Phase 2

Status: Completed

Sponsored by: Johns Hopkins University

Summary

The purpose of this study is to assess the comparative efficacy of retinol 1. 0% and tretinoin 0. 02% in minimizing wrinkles, discoloration, roughness, and other signs of moderate to severe photodamage. Our hypothesis is that both products will be of comparable benefit.

Clinical Details

Official title: Double-blinded, Single-center, Parallel-arm Comparison Study of Retinol 1.0% and Tretinoin 0.02% in the Treatment of Moderate to Severe Photodamage

Study design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Primary outcome: Global Photodamage Severity

Eligibility

Minimum age: 35 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Age 35 or over

- Moderate to severe photodamage

Exclusion Criteria:

- History of facial cosmetic surgery, facial resurfacing procedures, deep peels, or

facial fillers

- History of keloids or hypertrophic scars

- Use of oral steroids or oral retinoids (such as Accutane) in past 6 months

Locations and Contacts

Johns Hopkins Dept. of Dermatology, Baltimore, Maryland 21231, United States
Additional Information

SkinMedica, Inc., company website

Starting date: November 2010
Last updated: July 19, 2013

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017